Moving towards individualized medicine with pharmacogenomics

776 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Nanotechnology applications in cancer. (2007, background): “For applications in individualized therapy, biomarkers enable the characterization of patient populations and quantification of the extent to which new drugs reach their intended targets (41, 42).”
Pharmacogenomics and individualized drug therapy. (2006, methodology): “, receptors) are known to exhibit genetic polymorphisms that influence drug response in humans (1, 2, 99).”
Statistical strategies for avoiding false discoveries in metabolomics and related experiments (2007, background): “Note that this has nothing to do with the real stratification or differences in populations that are, for example, the focus of pharmacogenomics (Evans and Johnson, 2001; Evans and Relling, 1999, 2004) and analyses designed to reduce confounder effects (Rothman and Greenland, 1998).”
Pharmacogenomics in the clinic (2015, neutral): “EML–ALK (SV) inv(2)(p21p23) ALK Crizotinib NSCLC”